177Lu-CTR-FAPI for the Treatment of Thyroid Cancer

This is a multi-center, open-label, single-arm, dose-escalation phase I study, aiming to evaluate the safety and efficacy of 177Lu-CTR-FAPI (covalent targeted radioligand-fibroblast activation protein inhibitor), a novel radiopharmaceutical in the treatment of thyroid cancer. The primary endpoint of the study is the safety of 177Lu-CTR-FAPI, and the secondary endpoints include treatment response and dosimetry evaluation.

Trial Details

NCT ID
NCT07438847
Phase
PHASE1
Sponsor
SHAOYAN LIU
Status
RECRUITING
Cancer Type
Medullary Thyroid Cancer
Interventions
  • 177Lu-CTR-FAPI therapy
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Histologically confirmed diagnosis of thyroid cancer according to the 2022 WHO classification of thyroid tumors. Differentiated thyroid carcinoma m…
  • Evidence of progressive disease based on RECIST 1.1 criteria in pre-treatment imaging.
  • Prior surgical resection of resectable cervical lesions, with currently unresectable systemic disease.
  • Previous targeted therapy was discontinued due to intolerance, or lack of benefit from targeted therapy assessed by investigator, or patient refusal.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Medullary Thyroid Cancer Trials on Trialify →